REG - Physiomics PLC - Completion of Placing, Retail Offer & Notice of GM

PhysiomicsAnnouncement

10/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ9564Va&default-theme=true

RNS Number : 9564V  Physiomics PLC  10 March 2026

10 March 2026

 

 

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics completes Placing to fund growth opportunities

Launch of WRAP Retail Offer

Notice of General Meeting

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that it has completed
a placing, conditional on certain resolutions being passed at a general
meeting of the Company (the "General Meeting") and admission to trading on
AIM, of, in aggregate, £449,999.88 (gross) from the issue of 149,999,960 new
ordinary shares (the "Placing Shares") at an issue price of £0.003 per
Placing Share (the "Placing Price") through the Company's broker, Hybridan LLP
(the "Placing"). The Placing Price represents a discount of approximately
33.33 per cent. to the mid-market closing price of an existing ordinary share
on 9 March 2026 (being the latest practicable date prior to this
announcement).

 

The Company will also shortly be launching a retail offering to the Company's
existing shareholders to raise up to an additional £49,999.98 (or such other
amount as agreed by the Company) by way of the issue of a further 16,666,660
new ordinary shares (or such other number as agreed) (the "WRAP Retail Offer
Shares") at the Placing Price.

 

In order to further develop its business and continue its growth trajectory,
the Company is raising funds to carry out the following activities and for
general working capital:

·    Consulting Services (Modelling & Simulation and Biometrics)

o  Investment in business development and marketing to expand offering across
both service lines, including further development of later clinical phases and
engagement of large biopharmaceutical companies and contract research
organisations; and

o  Expansion of internal capabilities to support both services, including
development of new processes and data management solutions to support the
expanding offerings.

·    Personalised Medicine Tool Development

o  Continue development of the Company's Personalised Dosing Software.

·    Corporate

o  Exploration of strategic options to accelerate growth of modelling and
biometrics services and creation of new service-lines.

 

The Company has made significant progress since its last placing in February
2025, including:

·    Reporting a 46% year-on-year growth of total income for the financial
year ending 30 June 2025 and reporting a record half-year for total income for
the six-month period ending 31 December 2025. To date in FY26, the Company has
twice exceeded its best monthly revenue in comparison to FY 2025 with one
month achieving over £110k.

·    Appointment of Mr Jesse Thissen as Head of Biometrics and the
Company's first four contract awards for this new service line.

·    Continued expansion of the modelling and simulation service line into
new therapeutic areas, with projects supporting the development of new drugs
targeting arthritis, chronic obstructive pulmonary disease, coeliac disease,
and infectious diseases.

·    Continued diversification of client base, whilst still winning new
business with long-standing relationships such as Numab Therapeutics.

·    Implementation of the Company's Personalised Dosing Software onto the
DoseMeRx platform and expanded relationship with DoseMe Inc.

·    One peer-reviewed scientific article was published in partnership
with Ankyra Therapeutics, accompanied by several thought leadership pieces and
blog posts.

 

Retail Offering:

 

The Company is pleased to announce that a retail offer to existing
shareholders will be shortly launched via the Winterford Retail Access
Platform ("WRAP"), to raise up to an additional £49,999.98 (or such other
amount as agreed by the Company) (the "WRAP Retail Offer"), through the issue
of up to 16,666,660 new ordinary shares (or such other number as agreed) (the
"WRAP Retail Offer Shares"), at the Placing Price.

 

The proceeds of the WRAP Retail Offer will be utilised in the same way as the
proceeds of the Placing. For the avoidance of doubt, the WRAP Retail Offer is
not part of the Placing. Completion of the WRAP Retail Offer is conditional,
inter alia, upon the completion of the Placing, but completion of the Placing
is not conditional on the completion of the WRAP Retail Offer. The WRAP Retail
Offer is conditional on the WRAP Retail Offer Shares being admitted to trading
and certain resolutions being passed at the General Meeting.

 

The Company values its shareholder base and believes that it is appropriate to
provide its existing retail shareholders in the United Kingdom the opportunity
to participate in its fundraising.

 

The WRAP Retail Offer is expected to close at 4.30 p.m. on 12 March 2026.

 

 

Admission and Total Voting Rights

 

The Placing and WRAP Retail Offer are condition on, inter alia, certain
resolutions being passed at the General Meeting. The resolutions include: (i)
authority to reduce the nominal value of the Company's ordinary shares to
accommodate the Placing Price; (ii) authority, under section 551 of the
Companies Act 2006 to allot the Placing Shares and WRAP Retail Offer Shares;
and (iii) authority to allot the Placing Shares and WRAP Retail Offer Shares
for cash as if section 561 of the Companies Act 2006 did not apply to such
allotment. The General Meeting will be held on 7 April 2026.

 

Application will be made for the Placing Shares to be issued pursuant to the
Placing and the WRAP Retail Offer Shares to be issued pursuant to the WRAP
Retail Offer and each to be admitted to trading on AIM and dealing is expected
to commence on or around 8 April 2026 ("Admission"). A further announcement
regarding the enlarged issued share capital for the purposes of the Financial
Services Authority's Disclosure Guidance and Transparency Rules will be made
following completion of the Placing and the WRAP Retail Offer.

 

Notice of General Meeting

 

The Company also announces that it will be posting a notice convening a
general meeting of the Company ("Notice of GM") to be held at 10.00 a.m. on 7
April 2026 at Copthorne Hotel Slough-Windsor, Cippenham Lane, Slough,
Berkshire, SL1 2YE.

 

The general meeting is being convened to obtain authority from shareholders to
issue and allot shares relating to the placing and WRAP Retail Offer, as
announced today.

 

Shareholders will shortly be sent either printed copies of the Notice of GM or
a letter notifying them that the Notice of GM is available on the Company's
website, depending on the preferences they have expressed to the Company's
registrar.

 

A copy of the Notice of GM, containing further details of the resolutions to
be proposed at the meeting will be made available today on the Company's
website at www.physiomics.co.uk/investors/corporate-documents/
(http://www.physiomics.co.uk/investors/corporate-documents/) .

 

Dr Peter Sargent, CEO, commented:

 

"We want to thank our loyal and new shareholders for their support.  Over the
last twelve months, Physiomics has continued its growth journey and I am proud
that the Company has successfully expanded its offering, with the recent
launch of Biometrics service line as well as the expansion of its pre-existing
modelling and simulation service line. This expansion of services, along with
continued diversification of our client base, is testament to the quality and
flexibility we provide our clients and the impact our services bring to their
drug development efforts. The Company's revenue profile is improving with a
more diverse pipeline and significant visibility of future income. In the
last two years, the Company has had five new clients that have come back more
than once, helping our business increase the share of revenues which are
repeat.

 

The Directors believe that this growth will continue and that the Company is
on track to meet market expectations for this current year, which would
represent a record year for total income  of 27% growth based on market
expectations.

 

With this latest round of funding, investment is being made in key growth
initiatives across the business to continue our growth trajectory by investing
further in business development and marketing, as well as the exploration of
transformational opportunities that will accelerate growth."

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon publication of this announcement, this inside
information is now considered to be in the public domain.

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFFFSFVTIAIIR



            Copyright 2019 Regulatory News Service, all rights reserved